Document Detail


Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile.
MedLine Citation:
PMID:  17023232     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients at high risk for hypertension may require several therapeutic agents to lower their blood pressure to guideline-recommended targets. Some antihypertensive agents are more effective than others in protecting against cardiovascular morbidity and mortality. Numerous beta-blocking agents have been approved by the US Food and Drug Administration (FDA) for the treatment of hypertension. Previous trials have demonstrated that although all beta-blockers effectively reduce blood pressure, there are differences in how they affect various metabolic factors. In 2 trials, a novel controlled-release (CR) formulation of carvedilol will be tested against other selective beta-blockers to determine whether differences exist in their individual effects on cardiovascular risk factors. These will be the first head-to-head trials using carvedilol CR to determine whether the differing pharmacologic actions among beta-blockers result in varying effects on cardiovascular risk factors.
Authors:
George L Bakris; Elizabeth A Tarka; Brian Waterhouse; Michelle R Goulding; Anuradha Madan; Karen M Anderson; Martin St John Sutton; Alan B Miller; Nathaniel Reichek
Publication Detail:
Type:  Journal Article     Date:  2006-08-28
Journal Detail:
Title:  The American journal of cardiology     Volume:  98     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-10-06     Completed Date:  2007-02-20     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  46L-52L     Citation Subset:  AIM; IM    
Affiliation:
Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA. gbakris@earthlink.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / administration & dosage,  adverse effects,  therapeutic use*
Antihypertensive Agents / administration & dosage,  therapeutic use
Carbazoles / adverse effects,  therapeutic use*
Delayed-Action Preparations / adverse effects,  therapeutic use*
Drug Therapy, Combination
Dyslipidemias / blood,  complications,  drug therapy*
Humans
Hypertension / blood,  complications,  drug therapy*
Hypertrophy, Left Ventricular / blood,  complications,  drug therapy*
Hypolipidemic Agents / adverse effects,  therapeutic use
Propanolamines / adverse effects,  therapeutic use*
Randomized Controlled Trials as Topic
Research Design
Risk Factors
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Carbazoles; 0/Delayed-Action Preparations; 0/Hypolipidemic Agents; 0/Propanolamines; 0K47UL67F2/carvedilol
Comments/Corrections
Erratum In:
Am J Cardiol. 2007 Mar 15;99(6):878
Note: St John Sutton, Martin [added]; Miller, Alan B [added]; Reichek, Nathaniel [added]
Am J Cardiol. 2007 Aug 1;100(3):562

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfuncti...
Next Document:  COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection f...